Alkermes plc. — Director's Dealing 2024

Feb 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2024-02-18

Reporting Person: Nichols Christian Todd (SVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-18	Ordinary Shares	M	6355	—	Acquired	68161	Direct
2024-02-18	Ordinary Shares	F	1869	$32.18	Disposed	66292	Direct
2024-02-20	Ordinary Shares	M	3901	—	Acquired	70193	Direct
2024-02-20	Ordinary Shares	F	1379	$30.39	Disposed	68814	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-17	Employee Stock Option (Right to Buy)	$22.94	J	999	Acquired	2029-06-05	Ordinary Shares (999)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$20.03	J	885	Acquired	2030-02-20	Ordinary Shares (885)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	76	Acquired		Ordinary Shares (76)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$19.34	J	2274	Acquired	2031-02-22	Ordinary Shares (2274)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	278	Acquired		Ordinary Shares (278)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$24.59	J	1992	Acquired	2032-02-18	Ordinary Shares (1992)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	373	Acquired		Ordinary Shares (373)	Direct
2023-11-17	Employee Stock Option (Right to Buy)	$26.82	J	2010	Acquired	2033-02-23	Ordinary Shares (2010)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	502	Acquired		Ordinary Shares (502)	Direct
2024-02-18	Restricted Stock Unit Award	$	M	6355	Disposed		Ordinary Shares (6355)	Direct
2024-02-20	Restricted Stock Unit Award	$	M	3901	Disposed		Ordinary Shares (3901)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3: These options are fully vested in accordance with their terms.

F4: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

F5: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F6: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

F7: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F8: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

F9: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F10: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

F11: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.